# StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

> **NCT02765997** · PHASE2 · WITHDRAWN · sponsor: **Masonic Cancer Center, University of Minnesota**

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplasia

## Interventions

- **BIOLOGICAL:** Unmanipulated UCB
- **BIOLOGICAL:** SR-1 UCB

## Key facts

- **NCT ID:** NCT02765997
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-04
- **Primary completion:** 2020-06
- **Final completion:** 2022-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IRB Disapproval
- **Last updated:** 2017-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02765997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02765997, "StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02765997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*